More Than Pathogen Reduction: Seraph 100 In COVID-19 Patients

Start

Tue, 10 Nov 2020, 18:00

End

Tue, 10 Nov 2020, 19:00

WebSite

https://iii.hm/exthera2020

Venue:

Panelists:

Professor Jan Kielstein

(Klinikum Braunschweig, Germany)

Doctor Julius Schmidt

(Hannover Medical School, Germany)

Doctor Steven Stogner

(Forrest General Hospital in Hattiesburg, Mississippi, USA)

Doctor Brian Rifkin

(Forrest General Hospital in Hattiesburg, Mississippi, USA)

Find ExThera Medical On Social Media

Exhibit

Symposia

Workshops

Organiser

EXTHERA

ExThera Medical was formed in 2007 through a joint venture between the Emergence Venture Partners Life Science Incubator and ExThera AB, at the Karolinska Institute of Stockholm. We are focused on therapeutic applications to treat drug-resistant and drug-susceptible bloodstream infections in high-risk patient populations, with field deployable versions for biodefense and military.

The company’s first product, the Seraph® 100 Microbind® Affinity Blood Filter, is CE Marked for the reduction of pathogens during bloodstream infections in adjunction to antibiotics and commercially available in Europe.